194 related articles for article (PubMed ID: 16168650)
1. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate.
Wang Y; Li L; Jiang W; Yang Z; Zhang Z
Bioorg Med Chem Lett; 2006 Jun; 16(11):2974-7. PubMed ID: 16563756
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives.
Bisi A; Meli M; Gobbi S; Rampa A; Tolomeo M; Dusonchet L
Bioorg Med Chem; 2008 Jul; 16(13):6474-82. PubMed ID: 18522868
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of 7-oxo-7H-naphtho[1,2,3-de]quinoline derivatives as potential anticancer agents active on multidrug resistant cell lines.
Dzieduszycka M; Bontemps-Gracz MM; Stefańska B; Martelli S; Piwkowska A; Arciemiuk M; Borowski E
Bioorg Med Chem; 2006 May; 14(9):2880-6. PubMed ID: 16458007
[TBL] [Abstract][Full Text] [Related]
8. Fatty acyl amide derivatives of doxorubicin: synthesis and in vitro anticancer activities.
Chhikara BS; St Jean N; Mandal D; Kumar A; Parang K
Eur J Med Chem; 2011 Jun; 46(6):2037-42. PubMed ID: 21420207
[TBL] [Abstract][Full Text] [Related]
9. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
[TBL] [Abstract][Full Text] [Related]
10. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery.
Du JZ; Du XJ; Mao CQ; Wang J
J Am Chem Soc; 2011 Nov; 133(44):17560-3. PubMed ID: 21985458
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel amino-substituted xanthenones and benzo[b]xanthenones: evaluation of their antiproliferative activity and their ability to overcome multidrug resistance toward MES-SA/D x 5 cells.
Kostakis IK; Pouli N; Marakos P; Skaltsounis AL; Pratsinis H; Kletsas D
Bioorg Med Chem; 2006 May; 14(9):2910-34. PubMed ID: 16376546
[TBL] [Abstract][Full Text] [Related]
12. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization.
Lelle M; Frick SU; Steinbrink K; Peneva K
J Pept Sci; 2014 May; 20(5):323-33. PubMed ID: 24677287
[TBL] [Abstract][Full Text] [Related]
13. An antisense oligodeoxynucleotide-doxorubicin conjugate: preparation and its reversal multidrug resistance of human carcinoma cell line in vitro.
Ren Y; Wei D; Liu J; Su W
Nucleosides Nucleotides Nucleic Acids; 2004; 23(10):1595-607. PubMed ID: 15620098
[TBL] [Abstract][Full Text] [Related]
14. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
15. Modulation of doxorubicin activity in cancer cells by conjugation with fatty acyl and terpenyl hydrazones.
Effenberger K; Breyer S; Schobert R
Eur J Med Chem; 2010 May; 45(5):1947-54. PubMed ID: 20133021
[TBL] [Abstract][Full Text] [Related]
16. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region.
Flahaut M; Mühlethaler-Mottet A; Martinet D; Fattet S; Bourloud KB; Auderset K; Meier R; Schmutz NB; Delattre O; Joseph JM; Gross N
Genes Chromosomes Cancer; 2006 May; 45(5):495-508. PubMed ID: 16450357
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
18. Design of a tumor-homing cell-penetrating peptide.
Myrberg H; Zhang L; Mäe M; Langel U
Bioconjug Chem; 2008 Jan; 19(1):70-5. PubMed ID: 18001077
[TBL] [Abstract][Full Text] [Related]
19. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
